Krakow, 08 August 2014 – Selvita, Polish biotechnology company engaged in the discovery and development of breakthrough medicines to treat CNS, oncology and autoimmune disorders, as well as drug discovery services, has announced today that data from its SEL24 oncology program is scheduled to be reported at the ASH Meeting on Lymphoma Biology 2014, which will take place on August 10th – 13th 2014 in Colorado Springs, Colorado, USA
The data presented at the conference will include the most recent results obtained by scientists from the Institute of Hematology and Transfusion Medicine for clinical candidate SEL24-B489, developed by Selvita potentially best-in-class dual inhibitor of PIM/FLT3, in therapeutic areas such as Hodgkin’s lymphoma or chronic myeloid leukemia.
The poster presentation regarding results of the project in the area of Hodgkin’s lymphoma entitled “Inhibition of Pim kinases impairs NFκB activity and induces apoptosis in Hodgkin’s Lymphoma-derived cell lines” is scheduled to be presented at the poster session on Tuesday, August 12th from 4:00 pm to 5:30 pm in the Broadmoor Conference Center in Colorado Springs (poster number: 116).
The poster presentation entitled “Novel PIM Kinase Inhibitor SEL24-B489 Induces Apoptosis and Impairs CXCR4-mediated Migration of Chronic Lymphocytic Leukemia Cells” is scheduled to be presented at the poster session on Tuesday, August 12th from 4:00 pm to 5:30 pm in the Broadmoor Conference Center in Colorado Springs (poster number: 118).
“We are pleased to present the latest research results obtained for the PIM kinase inhibitor – compound SEL24-B489 at the prestigious American Society of Hematology conference – said Prof. Przemyslaw Juszczynski, IHT Scientific Director. Joint efforts of research teams from both institutions have shown that the mechanism of action of the molecule SEL24-B489 on PIM kinase activity is potentially applicable for the treatment of a broader spectrum of lymphatic system and hematopoietic cancers. In particular, for the first time the results show the strong inhibitory effects in diseases such as Hodgkin’s lymphoma or chronic lymphocytic leukemia.”
“We are extremely pleased with the results obtained for our clinical candidate SEL24-B489 by Professor Juszczynski’s team – adds Dr. Krzysztof Brzozka, Selvita’s Vice President and Chief Scientific Officer. Besides acute myeloid leukemia which was our main focus, the new data confirms the effectiveness of our compound in additional important therapeutic indications in which there is an urgent need for new treatments.”
Selvita is a Polish biotechnology company engaged in the discovery and development of breakthrough medicines to treat oncology, CNS and autoimmune disorders, as well as provision of drug discovery services. It was established in 2007 and currently employs 200 people, including 64 PhDs. Selvita has currently several internal projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2015. The most advanced programs at Selvita are SEL24, a pre-clinical PIM/FLT3 kinase inhibitor, with multiple indications in hematopoietic tumors and SEL120, first-in-class small molecule inhibitor of cyclin dependent kinase CDK8. Other innovative projects currently in development include SEL141, an early stage discovery program of DYRK1A kinase inhibitors with therapeutic potential in the treatment targeting Alzheimer’s disease and Down syndrome, SEL201 – novel small molecule MNK1/2 inhibitors in oncology, cancer metabolism platform and inflammasome platform. Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. Selvita is listed on the NewConnect market of the Warsaw Stock Exchange in Poland (SLV). Additional information about Selvita can be found on www.selvita.com
About Institute of Hematology and Transfusion Medicine (IHT)
IHT is a reference institution for diagnosing and treatment of patients with blood malignancies. It was established in 1951 and is the main scientific center in its disciplines in Poland as well as the main reference clinical diagnostic center. Each year, about 500 new patients with hematological malignancies are seen in the Institute’s outpatient and inpatients clinics. State-of-the-art diagnostic and therapeutic infrastructure and staff expertise allows for comprehensive diagnostic work-up and treatment of admitted patients, as well as post-treatment monitoring. As a reference institution in hematology, IHT sets the national guidelines for transfusion medicine, treatment of bleeding disorders and introduces research results to clinical practice. Additional information about the Institute of Hematology and Transfusion Medicine can be found on http://www.ihit.waw.pl/